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A combination therapy with pegylated interferon (PEG-IFN) plus ribavirin (RBV) has made it possible to achieve a sustained
virological response (SVR) of 50% in refractory cases with genotype 1b and high levels of plasma HCVRNA. Several factors
including virus mutation and host factors such as age, gender, ﬁbrosis of the liver, lipid metabolism, innate immunity, and single
nucleotide polymorphism (SNPs) are reported to be correlated to therapeutic eﬀects. However, it is diﬃcult to determine which
factor is the most important predictor for an individual patient. Data mining analysis is useful for combining all these together to
predict the therapeutic eﬀects. It is important to analyze blood tests and to predict therapeutic eﬀects prior to initiating treatment.
Since new anti-HCV agents are under development, it will be necessary in the future to select the patients who have a high
possibility of achieving SVR if treatment is performed with standard regimen.
1. Progress in Virological Response in the
Difﬁcult-to-Treat Patientswith Genotype1
HepatitisCVirus(HCV)Infectionand
Factors Correlated to the Efﬁcacy
Recently, the average age of the patients with chronic
hepatitis C has been increasing in Japan. Incidence of
hepatocellular carcinoma (HCC) in the elderly patients with
chronic hepatitis C (65 years or older) has demonstrated to
be higher than younger ones when adjusted by the stage of
hepatic ﬁbrosis [1]. In Japan, refractory cases with genotype
1b and high HCVRNA levels are seen in as high as 70
percent of chronic hepatitis C patients. The outcome of
conventional IFN monotherapy has been an SVR response
of 3%–5% after 6 months of treatment in genotype 1b
and high HCVRNA patients [2, 3], and virus mutation
such as interferon sensitivity-determining region (ISDR) is
shown to be correlated with the virological response [2].
The association of ISDR mutations and virological response
to IFN monotherapy was denied in an Italian study [4];
however, it was conﬁrmed by a Chinese study [5]a n da n
international meta-analysis [6].
However, pegylated IFN (PEG-IFN) extends the dura-
tion of therapy and reduces adverse eﬀects, and for this
reason, PEG-IFN has become the cornerstone of therapy.
Furthermore, by the combination therapy with PEG-IFN
and ribavirin (RBV), the rate of SVR has dramatically
improved. Even in the patients with genotype 1b and high
HCVRNA level, SVR rate reaches as high as 40%–50%,
thereby improving the therapeutic eﬀects both in Western
countries [7, 8] and in Japan [9, 10].
It is important to predict the rate of achieving SVR in the
individual patient, before initiating treatment. Both virus-
and host-related elements have been reported as factors
correlated to therapeutic eﬀects of combination therapy [11–
13]. A particular focus has been placed on virus mutations,
age, gender, ﬁbrosis of the liver, lipid metabolism, and degree
of fatty metamorphosis of the liver.
Among these factorsrelated to PEG-IFN and RBV, innate
immunity has been shown to be correlated in virological2 Hepatitis Research and Treatment
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Figure 1: Expression of genes correlated to the intrahepatic innate immunity and virological response to PEG-IFN alpha-2b and RBV
combinationtherapy.OpencolumnindicatesSVR(n = 30),graycolumnindicatesTR(n = 24),andclosedcolumnindicatesNVR(n = 20).
Error bars indicate the standard error. The P values were analyzed by the Kruskal-Wallis test. Expression of Rig-I was signiﬁcantly higher in
NVR than in SVR patients, and Cardif expression was higher in SVR than in NVR. The ﬁgure was cited from [8].
response. Asahina et al. reported that liver biopsies were
performed before the PEG-IFN and RBV combination
therapy to examine the correlation between the gene
expression involved in innate immunity and the therapeutic
eﬀects, and in the patients in whom RIG-I expression is high
and the expression of Cardif, an adaptor gene, is low, it was
found that there are many nonresponders (NVRs) in which
HCVRNA does not become negative during the course of
treatment [13]. It was therefore revealed that there are many
NVRs among the patients in whom the ratio of RIG-I to
Cardif in liver tissue is high and that this ratio is low in the
SVR patients. Based on these ﬁndings, it has become clear
that innate immunity is correlated to therapeutic eﬀects
(Figure 1).
Furthermore, it was recently discovered that a single
nucleotide polymorphism (SNP) of the host gene IL28B is
signiﬁcantlyinvolvedinthetherapeuticresponsetothePEG-
IFN and RBV combination therapy [14, 15]. The possibility
of becoming an NVR is high in cases of the minor allele
carriers of IL28B. However, it is not possible to routinely
measureanSNPofIL28Bintheclinicalsetting.Inthispaper,
factors which can actually be used in real clinical practice are
discussed for the prediction of the eﬃcacy of PEG-IFN and
RBV combination therapy.
2. Amount of HCVRNA
In the patients with chronic hepatitis C, it is not pos-
sible to directly measure the amount of virus, and the
amount of HCVRNA is measured instead. Currently, a
real-time PCR method which has an advantage of wide
range and high sensitivity is utilized, and measurements
can be taken from a single blood sample of a very small
amount, that is, 1.2logcopies/ml, to a very large amount,
that is, 8logcopies/ml. This method has a higher level of
sensitivity than the conventional Amplicor monitor test and
can therefore detect HCVRNA even if only a very small
amount exists in the plasma. If the amount of HCVRNA
in plasma is less than the range of sensitivity of the real-
time PCR method, it is recorded as undetectable level. If
the indication is “less than 1.2logcopies/ml of HCVRNA”,
it means that a very small amount of HCVRNA exists in the
plasma. Since the indication of the real-time PCR method
is based on log counts, a decrease of 1.0 in the numerical
value means that the amount of HCVRNA has decreased to
1/10. With the application of this real-time PCR method, it
h a sb e c o m ep o s s i b l et om e a s u r ea m o u n t so fH C V R N Au p
to 8logcopies/ml, and it has also become possible to predict
the eﬃcacy before treatment and to monitor appropriately
the reactivity during the course of treatment. However, in
the patients in whom a PEG-IFN and RBV combination
therapy is performed, SVR can be acquired even when
the amount of virus prior to the treatment is quite large.
It is therefore diﬃcult to predict the virological response
solely from the amount of HCVRNA before starting the
treatment. Once treatment has commenced, at what week
HCVRNA becomes negative is important for the prediction
of therapeutic eﬀects, and this serves as a parameter for
deciding the duration of treatment [16].Hepatitis Research and Treatment 3
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Figure 2: Comparison of aa70 mutations in the HCV core region
and the rate of HCVRNA becoming negative during the course of
treatment. Compared with the wild type, among the patients of
aa70 mutations, there were fewer patients in whom HCVRNA had
become negative during the course of treatment.
Measuring the rate of viral clearance from serum is
helpfulforpredictingthelikelihoodofaresponsetoPGEIFN
and RBV and useful for determining the optimal duration
of therapy if the patients start to receive the treatment
[17]. In the AASLD practice guideline, response-guided
therapy is highly recommended [18]. In two nationwide
registration trials conducted in Japan [9, 10], the SVR rate
was high, from 76% to 100%, in patients whose HCVRNA
was cleared rapidly from serum by week 4 (rapid virological
response; RVR), and 71% to 73% in patients who achieved
u n d e t e c t a b l eH C V R N Af r o mw e e k5t ow e e k1 2( e a r l y
virological response; EVR). In contrast, the SVR rate in
patients with late clearance of HCVRNA from week 13
to week 24 was low at 29% to 36%. No patients without
clearance of HCVRNA by week 24 achieved SVR.
The strategy of extending therapy in patients with
delayed virological responses, deﬁned as clearance of HCV-
R N Ab e t w e e nw e e k s1 2a n d2 4 ,w a se v a l u a t e di nﬁ v es t u d i e s
[19–23]. These results cannot be compared directly with
each other because of the heterogeneous study populations,
diﬀerences in the baseline characteristics, and the diﬀerent
regimens utilized amongst them. Nevertheless, the results
showed a trend toward a higher SVR rate by extending
therapy from 48 to 72 weeks in patients with delayed
virological response.
3. ViralMutationsinCore andNS5A Region
In the patients with genotype 1b HCV infection, the muta-
tions in aa70 and aa91 in the core region have been shown
to correlate with early virological response (EVR) during
PEG-IFN and RBV combination treatment [11]. If aa70 in
the core region is mutated to anything other than arginine
and aa91 to anything other than leucine, it is diﬃcult to
achieve EVR, and it is thus highly possible that such cases
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Figure 3: Number of ISDR substitutions and the comparison of
virological response, SVR, and relapse at the end of the treatment.
Compared with the patients with 2 or more sites of substitutions,
the rate of SVR was lower and the rate of relapse was higher in the
patients in whom there were fewer substitutions in ISDR, that is, 0
or 1 sites.
will become nonresponders. The examination results at our
institution including 292 patients with genotype 1b infection
demonstrated that, in the cases with mutations in aa70 in the
core region, the rate of HCVRNA becoming negative during
the course of combination treatment was low compared
to the wild type of aa70 (Figure 2). However, core aa70
mutationisshowntohavequasispeciesdetectablebycloning,
and 70Q clone was positively selected during combination
treatment with PEGIFN and RBV [24].
Furthermore, Enomoto et al. reported that the patients
w i t h4o rm o r ea m i n oa c i dm u t a t i o n sw e r eo b s e r v e d
in interferon sensitivity-determining region (ISDR) within
NS5A region [2]; SVR rate is higher than 90% by IFN
monotherapy, and SVR is less than 10% in the patients with
no mutation in ISDR. It has also been reported that, in PEG-
IFN and RBV combination therapy, the number of ISDR
mutations is involved in the SVR [12].
We analyzed the relationship between virological
response and ISDR mutations in the patients with genotype
1b infection treated by PEG-IFN alpha-2b and BRV
combination therapy. In the patients with 0 or 1 ISDR
mutation, even if the rate of HCVRNA becoming negative
at the end of treatment was the same, the rate of SVR would
be lower compared with the patients having 2 or more
mutations (Figure 3). This demonstrates that there is a
higher incidence of relapse after the end of treatment in the
patients with 0 or 1 ISDR mutation.
Enomoto and Maekawa reported that mutations both
in NS5A-ISDR (interferon sensitivity-determining region)
and core 70Q substitution are associated with no early viral
response during PEGIFN and RBV combination therapy
[25]. Association of core aa70 substitution and mutations
in NS5A region is conﬁrmed to be associated with viral
response by PEGIFN and RBV combination therapy in a
Japanese multicenter cooperative study [26]. The number of4 Hepatitis Research and Treatment
mutations in the interferon sensitivity-determining region
was shown to be associated with the viral response to
PEGIFN and RBV combination treatment not only in Japan
[27], but also in Tunisia [28].
Recently,aconsensushasbeenestablishedthatmutations
in aa70 in the core region are important for the prediction
of HCVRNA becoming negative during the early course of
treatment, and the number of ISDR mutations is important
for the prediction of relapse after the end of treatment.
4. Adherence
It has been conﬁrmed that it is important to ensure 80%
or more of the scheduled dose of both PEG-IFN and BBV
in order to improve the rate of SVR, and together with
the duration of treatment, the 80 · 80 · 80 rule has been
established. However, Schiﬀman et al. recently reported that
the dose of PEG-IFN in the initial stage of administration
is important and that, if a suﬃcient dose of PEG-IFN is
administered, then 60% or more of the RVB dose would be
enough [29]. It is therefore of primary importance to ensure
the dose of PEG-IFN.
In Japan, the average age of patients with chronic
hepatitis C is increasing, and achieving good adherence is
diﬃcult in many patients. Consequently, the rate of SVR is
low in elderly patients. How to improve the rate of SVR in
elderly patients is an important issue. With regard to the
dose of RBV, reducing the RBV dose based on the calculation
of the total body clearance (CL/F) has been proposed to
be useful for decreasing the discontinuation and improving
the rate of SVR. Although there is no consensus on an
appropriate dose of PEG-IFN in elderly patients, if the initial
dose is set lower than the usual dose, discontinuation would
be reduced. Thus, it is necessary to investigate whether such
an initial dose would improve the rate of SVR.
Recently, the risk of hemolytic anemia was clearly
demonstrated to correlate with ITAP gene SNP [30]. The
predictive implication should be analyzed prospectively in
clinical practice.
5. Host Factors
Zeuzem et al. described the factors related to the less
response to interferon-based therapy, and he showed that
several host factors such as older age, race, and obesity
are responsible factors for the poor response to IFN [31].
Recently, insulin resistance which was examined by home-
ostasis model assessment index (HOMA-IR) was shown to
be associated with a lower rate of SVR, and body mass index
(BMI) was not identiﬁed as a signiﬁcant factor for the poor
responsetoPEGIFNandribavirincombinationtherapy[32].
Insulin resistance was conﬁrmed as a related factor to the
nonresponse to interferon-based treatment [33]. However,
Charlton et al. reported that obesity itself is an associated
factor for decreased eﬃcacy of interferon-based therapies,
and they discussed the possible mechanism [34], and obesity
was shown to be associated with the increased enhancement
of suppressor of cytokine signaling (SOCS) family in the
hepatocytes [35].
6.DataMiningAnalysis
Both virus- and host-related factors are correlated to thera-
peutic eﬀects of PEG-IFN and RBV. One important question
is which of these factors should be focused on in order to
predict the therapeutic eﬀects in an individual patient. In
addition, in each individual patient, the host and virological
factors are diﬀerent. It is therefore diﬃcult to predict
the virological response in each case before treatment.
Furthermore, although it is important to predict the relapse
rate when HCVRNA becomes within an undetectable level
in an individual patient, prediction of the rate of SVR
including virological and host factors and adherence to
the treatment has never been carried out in an individual
patient.
A data mining analysis is the process of analyzing a
large amount of data by a computer in order to develop an
algorithm. Conventional statics have been used to examine
certain hypothesis. Data mining is superior in that it can set
an algorithm, using a computer, based on a large amount of
data without a hypothesis.
We therefore conducted at our institute a data mining
analysis of the patients with genotype 1b infection having
high levels of HCVRNA to whom a PEG-IFN alpha-2b and
RBV combination therapy was administered to investigate
whether by the 12th week after the commencement of
treatment HCVRNA became negative (EVR) (Figure 4)[ 36].
The most important factor for the prediction of EVR was
the steatosis of the liver: when steatosis was observed in 30%
or more of hepatocytes, EVR was found to be diﬃcult to
achieve. In the patients in whom steatosis was not severe, the
secondmostimportantfactorwastheserumLDLcholesterol
value. While the rate of EVR was 57% in the patients in
whom this value was 100mg/ml or above, the rate of EVR
was 32% in the patients in whom the LDL cholesterol was
less than 100mg/dl.
The higher the LDL cholesterol value, the earlier the
HCVRNA became negative. Among the patients with low
LDL cholesterol values, while the rate of EVR was 15% in
patients 60 years of age or older, the rate was high in the
patients under the age of 60 years old, that is, 49%. Among
patients under the age of 60, the rate of EVR was low, that is,
31%, in patients with a blood glucose level of 120mg/dl or
above whereas EVR was achieved in 71% of the patients with
a blood glucose level of less than 120mg/dl (Figure 4).
On the other hand, in the patients with high LDL
cholesterol values, the next most important factor was age.
While the rate of EVR was 50% in patients 50 years of age
or older, EVR was achieved in 77% of the patients under the
age of 50. Among patients of 50 years of age or older, the
nextmostimportantfactorwasthegammaGTPvalue.While
the rate of EVR was 35% in the patients in whom gamma
GTP was 40IU/L or above, EVR was achieved in 60% of the
patients where the value was less than 40IU/L.Hepatitis Research and Treatment 5
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Figure 4: HCVRNA negative (EVR) algorithm at 12th week from data mining analysis of PEG-IFN alpha-2b plus RBV combination in the
genotype 1b and high levels of HCVRNA. Both virological and host factors were evaluated by data mining analysis software from SPSS. This
ﬁgure was cited from [36].
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Figure 5: The rate of EVR in the patients with genotype 1b and high levels of HCVRNA, based on fatty deposition in the liver (a), and the
LDL cholesterol value (b), respectively. EVR was highly achieved in the patients with less steatosis in the liver, and in those with high serum
LDL-cholesterol levels. This is univariate analysis, and cited from [36].6 Hepatitis Research and Treatment
We therefore compared these factors based on the orig-
inal data. A univariate comparison of the fatty inﬁltration
of the liver and the rate of EVR demonstrated that the
rate of EVR was higher when the steatosis of the liver was
less severe (Figure 5(a)). In addition, a comparison of the
LDL cholesterol value and the rate of EVR demonstrated a
signiﬁcant correlation, conﬁrming that the higher the LDL
cholesterol value, the higher the rate of EVR (Figure 5(b)).
Therefore, it was also proposed by the results of univariate
analysis of each factor extracted from the data mining
analysis that these factors were correlated to the rate of EVR.
From these observations, it is likely to improve the viral
response to PEGIFN and ribavirin by reducing steatosis of
the liver through daily walking or abstinating alcohol intake
or by refraining from high-fat diet.
By utilizing data mining, it is therefore possible to assess
virus- and host-related factors together and to predict the
virological response in each patient, and thereby clinically
useful information can be obtained. The algorithm should
be validated including a large number of the patients.
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